DSM Biomedical proprietary polymers help customers, AxioMed and Sunshine Heart, reach commercial and clinical success
June 02 2009 - 9:00AM
Business Wire
DSM Biomedical, a global company serving the medtech and biotech
industries and part of Royal DSM N.V., announces two customers,
AxioMed Spine and Sunshine Heart, are celebrating commercial and
clinical success of their medical devices made with proprietary DSM
Biomedical polymers.
AxioMed� Spine Corp. has recently received CE Mark approval for
its Freedom� Lumbar Disc, an elastomeric total spinal disc
replacement device. The CE Mark clears AxioMed to introduce the
medical device into the European Union market. Using a patented
silicone-urethane copolymer under exclusive license from DSM
Biomedical, AxioMed�s lumbar disc is designed to replicate the
natural function of a human disc. The Freedom� Lumbar Disc was
developed and designed by AxioMed clinicians and experts in the
fields of biomechanics, pathology, and spine surgery in combination
with DSM Biomedical experts in polymer science and processing. The
material characteristics of DSM Biomedical�s polymer, in
combination with AxioMed�s implant design, provides
three-dimensional motion that mimics the natural biomechanics of
the spine.
�We believe our Freedom� disc may represent the next generation
of technology for treating degenerative disc disease,� said Patrick
McBrayer, AxioMed�s President and CEO. �The goal of our technology
is to restore the natural function of the spine. DSM Biomedical�s
polymer is well-suited to this goal. Its viscoelastic properties
allow for compression, rotation and translation, while
simultaneously providing load transfer and damping.�
Sunshine Heart Inc. recently announced that The Ohio State
University Medical Center has successfully completed the first two
implants of the Company�s C-Pulse� heart assist system under a
20-person clinical trial approved by the FDA. C-Pulse is designed
as a non-blood contacting heart assist therapy for treating
patients with moderate to severe heart failure, a condition in
which the heart progressively loses its ability to efficiently pump
blood throughout the body. The C-Pulse device, which must pulsate
up to 750,000 times per week, is made with two DSM Biomedical
polymers.
�We started working with DSM Biomedical on an exploratory
development program, advanced to a manufacturing program, and in
result have developed a very durable Cuff for the C-Pulse,� said
Donald Rohrbaugh, CEO of Sunshine Heart. �We are very pleased with
the partnership that has developed between Sunshine Heart and DSM
Biomedical.�
�We are very happy to partner with these two emerging medtech
companies,� added Bob Ward, President and CEO of DSM PTG, a part of
DSM Biomedical. �The major milestones achieved by AxioMed Spine and
Sunshine Heart occur within one year of the acquisition of The
Polymer Technology Group (PTG) by DSM. Today, the combined
resources of the former PTG and DSM ensure continued investment in
new technology for delivering biomedical materials that advance or
enable the development of next-generation medical devices.�
About DSM Biomedical
DSM Biomedical develops novel materials-based solutions to meet
the present and future needs of the medical device and
pharmaceutical industries. Building on the expertise and strengths
of DSM and its acquisition of DSM PTG (formerly The Polymer
Technology Group), the company�s product portfolio includes
coatings, drug delivery platforms and a wide range of biomedical
materials for use in short- and long-term implantable medical
devices. Key product brands include Bionate� TPU and CarboSil� TSPU, two of the most
extensively tested biomedical polymers ever developed. Both
polymers have excellent biostability, high strength and abrasion
resistance, making them candidate materials for load-bearing
orthopedic implants. ComfortCoat� hydrophilic and
antimicrobial coating technology for catheters, guidewires and
stent delivery systems; and Dyneema
Purity�, a high-performance polyethylene fiber technology
developed specifically for use in medical applications, such as
orthopedic implants. The company also markets the Trancerta� Drug Delivery approach, which
is based on DSM�s core strengths in polymers combined with its
extensive in-house library of synthesis methods, formulation and
processing techniques. For more information, visit
www.dsmbiomedical.com.
DSM � the Life Sciences and Materials Sciences
Company
Royal DSM N.V. creates innovative products and services in Life
Sciences and Materials Sciences that contribute to the quality of
life. DSM�s products and services are used globally in a wide range
of markets and applications, supporting a healthier, more
sustainable and more enjoyable way of life. End markets include
human and animal nutrition and health, personal care,
pharmaceuticals, automotive, coatings and paint, electrical and
electronics, life protection and housing. DSM has annual net sales
of EUR 9.3 billion and employs some 23,500 people worldwide. The
company is headquartered in the Netherlands, with locations on five
continents. DSM is listed on Euronext Amsterdam. More information:
www.dsm.com
About Sunshine Heart
Sunshine Heart (ASX: SHC) (www.sunshineheart.com) is a global
medical device company, committed to the commercialization of
C-Pulse� an implantable, non-blood contacting, heart assist therapy
for the treatment of people with moderate heart failure. C-Pulse
reduces the symptoms of heart failure through the use of
counterpulsation technology which enables an increase in cardiac
output, an increase in coronary blood flow and reduction in the
heart�s pumping workload. The Company has received approval from
the U.S. Food and Drug Administration (FDA) to conduct a 20 person
U.S. feasibility clinical trial with C-Pulse and patient enrolment
and implants have commenced. Sunshine Heart listed on the ASX in
September 2004 has a presence in Australia, New Zealand and the
United States of America.
Sunshine Heart (ASX:SHC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunshine Heart (ASX:SHC)
Historical Stock Chart
From Jul 2023 to Jul 2024